Search Results

search

Search Filters

Tag
Obesity
Rani-Logo.jpg
Rani Therapeutics to Participate in Upcoming Investor Conferences
November 07, 2024 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
November 05, 2024 07:00 ET | ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
Biologic Pharmamedical™ Reveals Capryl-Butyrate™ and necessary lifestyle changes for natural solutions for Gut Health, Mental Clarity, and Age-Defying Wellness
November 04, 2024 17:29 ET | Biologic Pharmamedical Inc.
This unveils the crucial role of a balanced microbiome in boosting immunity, metabolism, & mental clarity. Discover how gut health impacts longevity.
Fractyl-Logo.png
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
November 04, 2024 16:05 ET | Fractyl Health, Inc.
13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model Company plans to use durable...
Figure 1: Nasal anti-CD3 with Low and High Dose semaglutide promote Liver Homeostasis in DIO
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
October 30, 2024 08:30 ET | Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Fractyl-Logo.png
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
October 29, 2024 07:00 ET | Fractyl Health, Inc.
BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes...
Fractyl-Logo.png
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
October 28, 2024 07:00 ET | Fractyl Health, Inc.
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
October 22, 2024 09:54 ET | Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
October 22, 2024 07:57 ET | ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
October 21, 2024 07:30 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl